Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Steven A. Edmundowicz MD, MASGE Associate Editor

See All Experts

Published in Gastroenterology

Journal Scan / Research · September 24, 2021

Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis

Inflammatory Bowel Diseases

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Amar Naik MD

Inflammatory Bowel Diseases

Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data

Inflamm. Bowel Dis. 2021 Sep 01;27(9)1394-1408, JR Curtis, M Regueiro, H Yun, C Su, M DiBonaventura, N Lawendy, CI Nduaka, N Koram, JC Cappelleri, G Chan, I Modesto, GR Lichtenstein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis

Additional Info

Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data

Further Reading

PNPLA3 rs738409, Age, Diabetes, Sex, and Advanced Fibrosis Jointly Contribute to the Risk of Major Adverse Liver Outcomes in Patients With MASLD

Endoscopic Hemostasis With PuraStat for Colonic Diverticular Bleeding

Assessing the Pathophysiology of Crohn's-Like Disease of the Pouch Using Single-Cell Analysis of Mucosal Cells

Guidelines on the Pharmacological Management of Patients With Moderate to Severe Ulcerative Colitis

Infliximab Plus Azathioprine vs Azathioprine Alone in Patients With Acute Severe Ulcerative Colitis Responsive to IV Steroids

EsoGuard Plus EsoCheck for Non-Endoscopic Detection of Barrett's Esophagus

Pathophysiology, Diagnosis, and Management of Dumping Syndrome

Histological Predictors of Aggressive Recurrence of HCC After Liver Resection

Association Between Alcohol Consumption Levels and the Severity of MASLD

Once-Daily and Twice-Daily Topical Corticosteroids for Treating Patients With Eosinophilic Esophagitis

Outcomes of Using Subcutaneous Infliximab Biosimilar CT-P13 as Maintenance Therapy in Patients With IBD

Recently Updated